Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.73 |
| ▸ | PPARG | P37231 | 15/20 | 0.66 |
| ▸ | PPARA | Q07869 | 13/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850325 | 0.92 | FFAR1 (0.69) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL7559600 | 0.91 | KDR (0.83) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL4746637 | 0.90 | FFAR1 (0.77) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL3279259 | 0.89 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL4032011 | 0.88 | FFAR1 (0.70) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL4030957 | 0.88 | FFAR1 (0.70) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL4029049 | 0.88 | KDR (0.64) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL6156850 | 0.88 | FFAR1 (0.74) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL4845525 | 0.88 | KDR (0.66) | KDRFFAR1PPARGPPARAMAPT | |
| SCHEMBL4851678 | 0.87 | FFAR1 (0.70) | KDRFFAR1PPARGPPARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| CN-100482649-C | Organic compounds | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-7238716-B2 | Alkanoic acid derivatives process for their production and use thereof | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| EP-1664002-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20050239854-A1 | Body weight gain inhibitors | SUGIYAMA YASUO | 2005-10-27 | — | — | US | disclosed |
| US-6924300-B2 | Oxyiminoalkanoic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| WO-2005026134-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| EP-1304121-A1 | BODY WEIGHT GAIN INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6518435-B1 | Production method, a method of producing a compound represented by the formula (III) production method of oxyimino- alkanoic acid derivatives having an anti-diabetic activity. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-6495581-B1 | DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1227081-A1 | PROCESS FOR THE PREPARATION OF OXYIMINOALKANOIC ACID DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-1224178-A1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-24 | — | — | EP | disclosed |
| US-6251926-B1 | OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| WO-2001032637-A1 | CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-10 | — | — | WO | disclosed |
| EP-1077957-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 2001-02-28 | — | — | EP | disclosed |
| JP-2000034266-A | OXYIMINOALKANOIC ACID DERIVATIVE | TAKEDA CHEM IND LTD | 2000-02-02 | — | — | JP | disclosed |
| WO-1999058510-A1 | OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | KDR 649/4885FFAR1 18/4885PPARG 1/4885 |
| US-20050239854-A1 | Body weight gain inhibitors | PPARG, GPR119, PPARA | KDR 2397/4885FFAR1 43/4885PPARG 1/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | KDR 847/4885FFAR1 11/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.